Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV – Get Free Report) shares fell 28.2% on Wednesday . The company traded as low as $0.70 and last traded at $0.70. 305 shares were traded during trading, a decline of 63% from the average session volume of 829 shares. The stock had previously closed at $0.98.
Mosaic ImmunoEngineering Stock Performance
The business’s 50 day moving average price is $0.92 and its 200-day moving average price is $0.92. The firm has a market capitalization of $5.08 million, a PE ratio of -4.68 and a beta of 0.27.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.
Recommended Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- About the Markup Calculator
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- 3 Healthcare Dividend Stocks to Buy
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How to Calculate Inflation Rate
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
